Search Result

Results for "

PDZ

" in MedChemExpress (MCE) Product Catalog:

By Targets:	EGFR (1) FAK (1) iGluR (5) MMP (2) NF-κB (2) NO Synthase (2) TOPK (1) Wnt (2)
By Research Areas:	Cancer (8) Inflammation/Immunology (2) Metabolic Disease (2) Neurological Disease (7)

Inhibitors & Agonists

Peptides

Recombinant Proteins

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1195

PDZ1 Domain inhibitor peptide	iGluR	Neurological Disease
PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .

HY-124813

PDZ1i 113B7	FAK EGFR MMP	Cancer
PDZ1i is a potent, BBB-penetrated and specific MDA-9/Syntenin inhibitor. PDZ1i inhibits crucial GBM (glioblastoma multiforme) signaling involving FAK and EGFRvIII. PDZ1i reduces MMP secretion. PDZ1i can improve survival of brain tumor-bearing mice and reduce tumor invasion .

HY-117666

NSC668036 1 Publications Verification	Wnt	Inflammation/Immunology
NSC668036 is a *Dishevelled (Dvl) PDZ* domain inhibitor with a K_d of 237 µM. NSC668036 blocks Wnt** signaling by interrupting the Frizzled-Dvl interaction .

HY-P10164

Pen-N3	Wnt	Cancer
Pen-N3 is a PDZ peptide. Pen-N3 inhibits Wnt/b-catenin signaling by recognizing dishevelled protein .

HY-112920

TM-25659	Others	Metabolic Disease
TM-25659 is a *transcriptional co-activator with PDZ-binding motif (TAZ)* modulator. Anti-osteoporotic and anti-obesity activities .

HY-P1195A

PDZ1 Domain inhibitor peptide TFA	iGluR	Neurological Disease
PDZ1 Domain inhibitor peptide TFA, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide TFA disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .

HY-P10212

AVLX-125 UCCB01-125	iGluR	Neurological Disease
AVLX-125 (UCCB01-125) is a PSD-95 and PDZ domain inhibitor with K_d value of 10 nM. AVLX-125 can be used in the study of inflammatory pain .

HY-162510

SPDZi1	NF-κB	Cancer
SPDZi1 is a potent and selective syntenin inhibitor that binds to *PDZ1* and *PDZ2* domains of syntenin. SPDZi1 binds to the syntenin PDZ tandem (STNPDZ) with a K_d of 3.6 μM. SPDZi1 suppresses glioblastoma and reduces the activation of NF-κB, a downstream effector of syntenin .

HY-150269

RS5517	Others	Cancer
RS5517 is a specific PDZ1-domain antagonist of NHERF1 that prevented its ectopic nuclear entry. RS5517 can be used for the research of colorectal cancer .

HY-120346

PBK-IN-9	TOPK	Cancer
PBK-IN-9 (compound 1160) is a potent PDZ binding kinase (PBK) inhibitor .

HY-156247

IVMT-Rx-3	NF-κB MMP	Cancer
IVMT-Rx-3 is a inhibitor of SDCBP targeting of the *PDZ1* and *PDZ2* Domains of MDA-9/Syntenin. IVMT-Rx-3 blocks MDA-9/Syntenin interaction with Src, reduces NF-κB activation, and inhibits MMP-2/MMP-9 expression. IVMT-Rx-3 inhibits Melanoma Metastasis ^[1]

HY-117772

FSC231	Others	Metabolic Disease Inflammation/Immunology
FSC231 is a PSD‐95/DLG/ZO‐1 (PDZ) domain inhibitor of PICK1. FSC231 has analgesic effects .

HY-149204

SYNTi	Others	Cancer
SYNTi is a PDZ domain inhibitor targeting the syndecan/syntenin protein-protein Interaction. SYNTi exhibits an IC₅₀ value of 400 nM and ligand efficiency (LE) value of 0.24. SYNTi can be used for breast cancer research .

HY-P0117A

Tat-NR2B9c TFA Maximum Cited Publications 8 Publications Verification Tat-NR2Bct TFA; NA-1 TFA	iGluR NO Synthase	Neurological Disease
Tat-NR2B9c TFA (Tat-NR2Bct TFA) is a postsynaptic density-95 (PSD-95) inhibitor, with EC₅₀ values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c TFA disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC₅₀ values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c TFA also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy .

HY-P0117

Tat-NR2B9c Maximum Cited Publications 8 Publications Verification Tat-NR2Bct; NA-1	iGluR NO Synthase	Neurological Disease
Tat-NR2B9c (Tat-NR2Bct; NA-1) is a postsynaptic density-95 (PSD-95) inhibitor, with EC₅₀ values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC₅₀ values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c also inhibits?neuronal nitric oxide synthase (nNOS)/PSD-95?interaction, and possesses neuroprotective efficacy .

Cat. No.	Product Name	Target	Research Area

HY-P1195

PDZ1 Domain inhibitor peptide	iGluR	Neurological Disease
PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .

HY-P10164

Pen-N3	Wnt	Cancer
Pen-N3 is a PDZ peptide. Pen-N3 inhibits Wnt/b-catenin signaling by recognizing dishevelled protein .

HY-P0117A

Tat-NR2B9c TFA 5+ Cited Publications Tat-NR2Bct TFA; NA-1 TFA	iGluR NO Synthase	Neurological Disease
Tat-NR2B9c TFA (Tat-NR2Bct TFA) is a postsynaptic density-95 (PSD-95) inhibitor, with EC₅₀ values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c TFA disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC₅₀ values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c TFA also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy .

HY-P0117

Tat-NR2B9c 5+ Cited Publications Tat-NR2Bct; NA-1	iGluR NO Synthase	Neurological Disease
Tat-NR2B9c (Tat-NR2Bct; NA-1) is a postsynaptic density-95 (PSD-95) inhibitor, with EC₅₀ values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC₅₀ values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c also inhibits?neuronal nitric oxide synthase (nNOS)/PSD-95?interaction, and possesses neuroprotective efficacy .

HY-P1195A

PDZ1 Domain inhibitor peptide TFA	iGluR	Neurological Disease
PDZ1 Domain inhibitor peptide TFA, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide TFA disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .

HY-P10212

AVLX-125 UCCB01-125	iGluR	Neurological Disease
AVLX-125 (UCCB01-125) is a PSD-95 and PDZ domain inhibitor with K_d value of 10 nM. AVLX-125 can be used in the study of inflammatory pain .

HY-P2298

TAT-P4-(DATC5)2	Peptides	Neurological Disease
TAT-P4-(DATC5)2 is a high-affinity peptide inhibitor of the *PICK1 (protein interacting with C kinase-1) PDZ* domain, with a K_i** of 1.7 nM. TAT-P4-(DATC5)2 can inhibit addiction in rats .

HY-P2298A

TAT-P4-(DATC5)2 TFA	Peptides	Neurological Disease
TAT-P4-(DATC5)2 TFA is a high-affinity peptide inhibitor of the *PICK1 (protein interacting with C kinase-1) PDZ* domain, with a K_i** of 1.7 nM. TAT-P4-(DATC5)2 TFA can inhibit addiction in rats .

HY-P10331

KSL 128114	Peptides	Cancer
KSL 128114, a peptide inhibitor of syntenin, binds the PDZ1 domain of syntenin with nanomolar affinity. KSL 128114 is resistant toward degradation in human plasma and mouse hepatic microsomes and displays a global PDZ domain selectivity for syntenin .

Species:	Human (4)
Tag:	His (4)
Source:	E. coli (4)

Cat. No.	Compare	Product Name	Species	Source

HY-P77130

	PDZD11 Protein, Human (His) PDZ domain-containing protein 11; PMCA-interacting single-PDZ protein; AIPP1; PDZK11; PISP	Human	E. coli
	PDZD11 protein is a key mediator that promotes the docking of ADAM10 to adhesion zonules by interacting with PLEKHA7. PDZD11 is critical for subsequent binding to TSPAN33, which orchestrates complex protein-protein interactions at cellular junctions. PDZD11 Protein, Human (His) is the recombinant human-derived PDZD11 protein, expressed by E. coli , with N-His labeled tag.

HY-P75331

	CRIPT Protein, Human (His) Cysteine-rich PDZ-binding protein; CRIPT; HSPC139	Human	E. coli
	CRIPT, a pivotal member of the minor spliceosome, plays a crucial role in U12-type intron splicing, contributing to RNA splicing intricacies. Beyond its splicing function, CRIPT anchors DLG4 within excitatory synapses, interacts with RNF113A, SF3B1/SF3b155, SF3B2/SF3b145, and PHF5A/SF3b14b in the minor spliceosome complex, and strongly associates with the PDZ3 domain of DLG4 family members, highlighting its synaptic involvement. Additionally, CRIPT interacts with microtubules, indicating a role in cytoskeletal dynamics, showcasing its multifaceted contributions. CRIPT Protein, Human (His) is the recombinant human-derived CRIPT protein, expressed by E. coli, with N-His labeled tag. The total length of CRIPT Protein, Human (His) is 101 a.a., with molecular weight of ~14 kDa.

HY-P73708

	PIST Protein, Human (His) Golgi-associated PDZ and coiled-coil motif-containing protein; PIST; GOPC; CAL; FIG	Human	E. coli
	PIST (PDZ domain-containing protein that interacts with Stx6) is critical in intracellular protein trafficking and degradation. It modulates CFTR chloride currents and acid-induced ASIC3 currents, thereby potentially regulating their cell surface expression. PIST Protein, Human (His) is the recombinant human-derived PIST protein, expressed by E. coli , with N-His labeled tag.

HY-P76966

	USH1C Protein, Human (His) Harmonin; Antigen NY-CO-38/NY-CO-37; Protein PDZ-73; AIE75	Human	E. coli
	USH1C is an anchoring and scaffolding protein critical for cochlear hair cell mechanotransduction. It forms a network with USH1G, CDH23 and MYO7A and contributes to the development and maintenance of hair cell bundles. USH1C Protein, Human (His) is the recombinant human-derived USH1C protein, expressed by E. coli , with N-6*His labeled tag. The total length of USH1C Protein, Human (His) is 552 a.a., with molecular weight of ~70 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81820

	PDLIM1 Antibody (YA1565) PDLIM1; CLIM1; CLP36; PDZ and LIM domain protein 1; C-terminal LIM domain protein 1; Elfin; LIM domain protein CLP-36	WB, ICC/IF, IP	Human, Mouse, Rat
	PDLIM1 Antibody (YA1565) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1565), targeting PDLIM1, with a predicted molecular weight of 36 kDa (observed band size: 36 kDa). PDLIM1 Antibody (YA1565) can be used for WB, ICC/IF, IP experiment in human, mouse, rat background.

HY-P81511

	PBK Antibody (YA1256) PBK; TOPK; Lymphokine-activated killer T-cell-originated protein kinase; Cancer/testis antigen 84; CT84; MAPKK-like protein kinase; Nori-3; PDZ-binding kinase; Spermatogenesis-related protein kinase; SPK; T-LAK cell-originated protein kinas	IHC-P	Human
	PBK Antibody (YA1256) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1256), targeting PBK. PBK Antibody (YA1256) can be used for IHC-P experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: